Recent Comments

Comment RSS

Stent News and Research RSS Feed - Stent News and Research

A stent is a small mesh tube that’s used to treat narrowed or weakened arteries in the body.

You may have a stent placed in an artery as part of a procedure called angioplasty (AN-jee-oh-plas-tee). Angioplasty can restore blood flow through narrowed or blocked arteries. Stents help prevent arteries from becoming narrowed or blocked again in the months or years after treatment with angioplasty. You may also have a stent placed in a weakened artery to improve blood flow and to help prevent the artery from bursting.

Stents are usually made of metal mesh, but sometimes they’re made of fabric. Fabric stents, also called stent grafts, are used in larger arteries. Some stents are coated with medicines that are slowly and continuously released into the artery. These medicines help prevent the artery from becoming blocked again.

Boston Scientific's WallFlex Fully Covered Esophageal Stent receives FDA clearance and CE Mark approval

20. November 2009 09:14
Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval to market its WallFlex® Fully Covered Esophageal Stent for the treatment of malignant esophageal strictures (obstructions) caused by tumors in patients with resectable or non-resectable esophageal cancer. [More]

Posted in: Device / Technology News | Medical Condition News

Tags: , , , , ,

Cardiovascular Systems commences patient enrollment in CALCIUM 360° clinical trial

19. November 2009 08:45
Cardiovascular Systems, Inc., announces the first patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company’s 360° Clinical Series. The CALCIUM 360° study will evaluate the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI’s Diamondback 360® PAD System, a minimally invasive catheter for treating PAD anywhere in the leg. [More]

Medtronic introduces imaging and visualization service for endovascular specialists

19. November 2009 07:42
Continuing to drive innovation in endovascular aortic repair (EVAR), Medtronic, Inc., today announced the introduction of an imaging and visualization service for endovascular specialists who use the company’s market-leading portfolio of stent grafts to treat aortic aneurysms. Aortic aneurysms affect more than one million people in the United States alone and can rupture with fatal consequences if left untreated. [More]

Posted in: Device / Technology News | Healthcare News

Tags: ,

Updated clinical guidelines on Effient treatment for ACS patients

19. November 2009 06:53
Effient® (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardial infarction (STEMI), or severe heart attack. [More]

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

19. November 2009 00:49
Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus. [More]

Endologix receives IDE conditional approval from FDA

19. November 2009 00:14
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has received Investigational Device Exemption (IDE) conditional approval from the United States Food and Drug Administration ("FDA") to begin a prospective, multicenter, randomized clinical trial for a bilateral percutaneous approach to endovascular abdominal aortic aneurysm repair (EVAR) utilizing the Company's IntuiTrak(TM) endovascular delivery system for the Powerlink® family of stent grafts. [More]

Posted in: Device / Technology News

Tags: ,

W. L. Gore to distribute QXMédical's Q50 Stent Graft Balloon Catheter

18. November 2009 08:47
W. L. Gore & Associates today announced it has entered into a partnership with QXMédical, LLC, a medical device development and marketing company. As part of the agreement, Gore will distribute the Q50 Stent Graft Balloon Catheter which is designed for use with aortic stent grafts that treat abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA). [More]

Posted in: Device / Technology News

Tags: , , ,

Report on the 2009 European markets for peripheral vascular devices

18. November 2009 04:39
In 2008, the European market for peripheral vascular devices was valued at euro 623 million, an increase of 3.4% over 2007. This value represents the market for stents, PTA balloons, embolic protection devices, vena cava filters, stent-grafts, surgical grafts, interventional catheters and guidewires, introducer sheaths, diagnostic catheters and guidewires, and vascular closure devices. [More]

Posted in: Device / Technology News

Tags: ,

Atrium Medical presents interim results from its COBEST clinical study at the 2009 VIVA meeting

17. November 2009 08:22
Atrium Medical Corporation is proud to announce the release of the interim results from the COBEST clinical study. This study is to evaluate the use of bare metal stents vs. balloon expandable covered stents for the treatment of aorto-iliac occlusive disease. Prof. Patrice Mwipatayi of Royal Perth Hospital, Australia, presented interim data on the Covered versus Balloon Expandable Stent Trial known as COBEST at the 2009 VIVA (Vascular InterVentional Advances) meeting in Las Vegas. [More]

Posted in: Device / Technology News | Medical Condition News

Tags: , , , , ,

New, reversible antiplatelet drug not superior than irreversible one in patients undergoing PCI

17. November 2009 04:22
A new, reversible antiplatelet drug did not demonstrate superiority over a current irreversible one in reducing the composite of death, heart attack or ischemia-related revascularization in the 48 hours after angioplasty, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009. [More]

Posted in: Medical Procedure News | Medical Condition News | Pharmaceutical News

Tags: , , , ,

Incidence of stroke related to coronary angioplasty remain steady over a 15-year period: Mayo Clinic study

17. November 2009 03:39
Results of a Mayo Clinic study show the incidence of stroke or mini-stroke related to a coronary angioplasty (http://www.mayoclinic.org/heart-catheterization/types.html) remained steady over a 15-year period. Researchers say this is good news because physicians now are performing the artery-opening procedure on older patients who are sicker and need more complicated treatment. [More]

Posted in: Medical Condition News

Tags: , , , ,

Platelet function tests predict heart attacks in patients pre-treated with two anti-clotting medications before coronary stenting

16. November 2009 08:35
Three platelet function tests all identified heart patients who will have blood cells that remain sticky, increasing heart attack risk, despite being pre-treated with two anti-clotting medications before coronary stenting, researchers reported at the American Heart Association's Scientific Sessions 2009. [More]

Posted in: Device / Technology News | Medical Condition News

Tags: , , , , , , ,

New reversible blood thinner for angioplasty patients not superior over placebo

16. November 2009 04:30
A new reversible blood thinner for angioplasty patients wasn't superior over placebo for its primary combined endpoint of heart attack, all-cause mortality and need for revascularization, but it reduced mortality and in-stent blood clots, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009. [More]

Posted in: Drug Trial News

Tags: , , , , , , ,

New reversible oral anti-platelet medication had fewer cardiac events in heart attack patients

16. November 2009 04:15
Acutely ill heart attack patients who received both aspirin and a new reversible oral anti-platelet medication had fewer cardiac events than patients on aspirin and the most commonly used, irreversible anti-platelet drug, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , ,

Cappella commences evaluation of the Sideguard Coronary Sidebranch Stent & Delivery System

16. November 2009 03:47
Cappella, Inc., a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, announced the start of Sideguard 3, an IVUS/OCT evaluation of the Sideguard® Coronary Sidebranch Stent & Delivery System. This is a European multicenter study to evaluate the vascular response to Sideguard in de novo bifurcation lesions of native coronary arteries. [More]

Posted in: Device / Technology News

Tags: ,

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.